 |
| Company |
Product name
/number |
Product
type |
Phase of development |
Status and
comment
(October 1997) |
| PC |
I |
II |
III |
L |
|
| Amgen-Synergen |
rHuIL-1Ra |
Genetically engineered
'biological' |
 |
 |
|
|
|
Blocks the IL-1 receptor |
|
| ASTA Medica |
Penicilamine |
DMARD |
|
|
 |
 |
 |
|
|
| Boehringer
Ingelheim |
Meloxicam |
Oxicam-NSAID |
|
|
|
|
|
Some selectivity for COX-2
claimed. Licensed in some countries |
| Enlimomab |
Monoclonal antibody |
|
|
|
|
|
Blocks ICAM-1 on blood
vessels making them less 'sticky' |
|
| Celltech |
CDP-571 |
Genetically engineered
human antibody |
|
|
|
|
|
Blocks the action of TNF |
| CDP-855 |
Genetically engineered
antibody |
|
|
|
|
|
May have other applications
as well as for RA |
|
| Chiroscience |
PNP inhibitor |
Inhibitor of cell division |
|
|
|
|
|
Inhibits nucleic acid
synthesis |
| CH-3298 |
MMp and TNFx-release inhibitor |
|
|
|
|
|
|
|
| E Merck |
Acemetacin |
NSAID |
|
|
|
|
|
Chemically related to
indomethacin |
|
| Glaxo Wellcome |
GW353430 |
Monoclonal antibody |
|
|
|
|
|
Blocks the CD23 receptor |
| GR 253035 |
COX-2 inhibitor |
|
|
|
|
|
|
| 4162W94 |
Monoclonal antibody |
|
|
|
|
|
Blocks CD4 receptor |
| Azathioprine |
DMARD |
|
|
|
|
|
|
|
| Hoechst
Marion Roussel |
Tiaprofenic
acid |
NSAID |
|
|
|
|
|
For inflamation
and pain relief |
| IL-1B inhibitor |
Genetically
engineered 'biological' |
|
|
|
|
|
|
| Leflunomide |
Immuno-regulator
and anti-inflammatory |
|
|
|
|
|
Compound with
novel action. Filing for registration 1998 |
|
| Knoll |
Ibuprofen retard |
NSAID |
|
|
|
|
|
A sustained release tablet
formulation |
| Flurbiprofen SR |
NSAID |
|
|
|
|
|
A sustained release capsule
formulation |
|
| Eli
Lilly |
IL-2 fusion
toxin |
Genetically
engineered 'biological' |
|
|
|
|
|
Would block
CD25 receptor |
| Penicilamine |
DMARD |
|
|
|
|
|
|
| Fenoprofen |
NSAID |
|
|
|
|
|
|
|
| Merck Sharp
& Dohme |
Sulindac |
NSAID |
|
|
|
|
|
|
| MK966 |
COX-2 inhibitor |
|
|
|
|
|
|
|
| Napp |
SR Indomethacin |
NSAID |
|
|
|
|
|
Indomethacin
in a slow-release form |
Ibuprofen/
codenine |
NSAID + analgesic |
|
|
|
|
|
Combination
to relieve inflammation and pain |
| SR Morphine
/ dihydrocodieine |
Narcotic analgesic |
|
|
|
|
|
Tablets, capsules
and suspensions for sevre intractable pain, including
RA |
|
| Novartis |
Phenylbutazone |
NSAID |
|
|
|
|
|
For hospital |
| Diclofenac |
NSAID |
|
|
|
|
|
|
| Cyclosporin |
Immuno - suppressive |
|
|
|
|
|
Classed as
a DMARD but has an immuno - suppressive action |
| CD-4 blocker |
Genetically
engineered 'biological' |
|
|
|
|
|
Will block
the release of harmful cytokines |
|
| Organon |
Rimexolone |
Gluco-corticoid |
|
|
|
|
|
|
|
| Parke Davis |
Diclofenac
retard |
NSAID |
|
|
|
|
|
Trials planned
for UK |
| OPC-14597 |
Dopamine agonist |
|
|
|
|
|
|
|
| Pfizer |
Piroxicam |
Oxicam NSAID |
|
|
|
|
|
|
|
| Pharmacia & Upjohn |
Sulfasalazine |
DMARD |
|
|
|
|
|
|
|
| Proteus International |
NISV |
Immune response modifier |
|
|
|
|
|
A novel technology for
damping down immune responses |
|
| Rhone-Poulenc Rorer |
Myocrsin |
DMARD |
|
|
|
|
|
Injectable gold salt |
| Ketoprofen |
NSAID |
|
|
|
|
|
|
| Chloroquine |
DMARD |
|
|
|
|
|
|
|
| Roche |
Naproxen |
NSAID |
|
|
|
|
|
|
| Tenoxicam |
Oxicam-NSAID |
|
|
|
|
|
|
| Mycophenoplate mofeti |
Immuno-suppressive |
|
|
|
|
|
Licensed for transplant
rejection but not yet for RA |
Trocade
(Ro32-3555) |
Collagenase inhibitor |
|
|
|
|
|
May prevent joint destruction |
|
| Sanofi Winthrop |
Benorylate |
NSAID + analgesic |
|
|
|
|
|
An unusual prodrug form
form of aspirin and paracetamol |
| Hydroxy-chloroquine |
DMARD |
|
|
|
|
|
|
| ISR-31747 |
Peripheral sigma receptor
antagonist |
|
|
|
|
|
|
|
| Schering-Plough |
IL-10 |
Genetically
engineered cytokine |
|
|
|
|
|
Expected to
suppress the effects of other inflammatory cytokines |
|
| Scotia |
Gammalinolenic
acid |
Essential
fatty acid |
|
|
|
|
|
|
| Eicosapentaenoic
acid |
Essential
fatty acid |
|
|
|
|
|
|
|
| Searle |
Diclofenac / misoprostal |
NSAID / prostaglandin
anti-ulcer combination |
|
|
|
|
|
Combination as a single
formulation |
| Naproxen / misoprostal |
NSAID + prostaglandin
analogue |
|
|
|
|
|
Combination pack |
| Celecoxib |
COX-2 inhibitor |
|
|
|
|
|
|
| Tramadol |
Analgesic |
|
|
|
|
|
|
|
| SmithKline Beecham |
Nabumetone |
Non-acid NSAID |
|
|
|
|
|
|
| SB-210396 |
Monoclonal antibody |
|
|
|
|
|
Will block release of
harmful cytokines |
| SB-217969 |
Monoclonal antibody |
|
|
|
|
|
Will block release of
harmful cytokines |
|
| Trinity |
Indomethacin SR |
NSAID |
|
|
|
|
|
Slow-release form of indomethacin |
| Ketoprofen |
NSAID |
|
|
|
|
|
|
| Mefenamic acid |
NSAID |
|
|
|
|
|
For pain relief in RA
and some other inflammatory conditions |
| Diclofenac SR |
NSAID |
|
|
|
|
|
Slow release form of diclofenac |
|
| Wyeth |
Methotrexate |
DMARD |
|
|
|
|
|
|
| Fenbufen |
NSAID |
|
|
|
|
|
Marketed by Genus, a division
of Wyeth |
| Azapropazone |
NSAID |
|
|
|
|
|
|
|
| Xenova |
Pharma Projects
3463 |
Immunological |
|
|
|
|
|
|
|
| Yamanouchi |
Auranofin |
DMARD |
|
|
|
|
|
Gold salt
in tablet form |
|
| Zeneca |
ZD2315 |
MHC II antagonist |
|
|
|
|
|
Will block release of
harmful cytokines |
| ZD4953 |
PG1 receptor antagonist |
|
|
|
|
|
For musculoskeletal pain |
| ZD7349 |
VLA4 adhesion blocker |
|
|
|
|
|
May block immune cell
migration into joint |
